CN101953794A - 一种水飞蓟宾注射剂及制备方法 - Google Patents
一种水飞蓟宾注射剂及制备方法 Download PDFInfo
- Publication number
- CN101953794A CN101953794A CN2009100698012A CN200910069801A CN101953794A CN 101953794 A CN101953794 A CN 101953794A CN 2009100698012 A CN2009100698012 A CN 2009100698012A CN 200910069801 A CN200910069801 A CN 200910069801A CN 101953794 A CN101953794 A CN 101953794A
- Authority
- CN
- China
- Prior art keywords
- silibinin
- injection
- preparation
- silybinin
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 title claims abstract description 153
- 238000002360 preparation method Methods 0.000 title claims abstract description 133
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 title claims abstract description 120
- 229950000628 silibinin Drugs 0.000 title claims abstract description 119
- 235000014899 silybin Nutrition 0.000 title claims abstract description 119
- 238000002347 injection Methods 0.000 title claims abstract description 43
- 239000007924 injection Substances 0.000 title claims abstract description 43
- 239000000243 solution Substances 0.000 claims abstract description 98
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 83
- 239000000843 powder Substances 0.000 claims abstract description 73
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 54
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 46
- 239000000203 mixture Substances 0.000 claims abstract description 26
- 238000004108 freeze drying Methods 0.000 claims abstract description 23
- 239000003708 ampul Substances 0.000 claims abstract description 20
- 238000001694 spray drying Methods 0.000 claims abstract description 14
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 13
- 230000001954 sterilising effect Effects 0.000 claims abstract description 12
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 63
- 239000002904 solvent Substances 0.000 claims description 46
- 239000008215 water for injection Substances 0.000 claims description 42
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 27
- 239000011734 sodium Substances 0.000 claims description 27
- 229910052708 sodium Inorganic materials 0.000 claims description 27
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 24
- 239000008103 glucose Substances 0.000 claims description 24
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 claims description 23
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 claims description 23
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 claims description 23
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 22
- 102000002322 Egg Proteins Human genes 0.000 claims description 22
- 108010000912 Egg Proteins Proteins 0.000 claims description 22
- 241000287828 Gallus gallus Species 0.000 claims description 22
- 239000000787 lecithin Substances 0.000 claims description 22
- 229940067606 lecithin Drugs 0.000 claims description 22
- 235000010445 lecithin Nutrition 0.000 claims description 22
- 210000004681 ovum Anatomy 0.000 claims description 22
- 229960004756 ethanol Drugs 0.000 claims description 20
- 239000012528 membrane Substances 0.000 claims description 19
- 238000002390 rotary evaporation Methods 0.000 claims description 18
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 17
- 229940083466 soybean lecithin Drugs 0.000 claims description 17
- 238000001035 drying Methods 0.000 claims description 16
- 206010013786 Dry skin Diseases 0.000 claims description 15
- 229930006000 Sucrose Natural products 0.000 claims description 15
- 239000005720 sucrose Substances 0.000 claims description 15
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 14
- 229940099352 cholate Drugs 0.000 claims description 13
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 13
- 238000004659 sterilization and disinfection Methods 0.000 claims description 11
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 9
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims description 9
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 8
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 8
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 8
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims description 5
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims description 5
- 229920001503 Glucan Polymers 0.000 claims description 4
- WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 claims description 4
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 4
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 claims description 4
- FKJIJBSJQSMPTI-CAOXKPNISA-M sodium;(4r)-4-[(5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-3,7,12-trioxo-1,2,4,5,6,8,9,11,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound [Na+].C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C FKJIJBSJQSMPTI-CAOXKPNISA-M 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 244000173166 Pyrus ussuriensis Species 0.000 claims 1
- 235000011572 Pyrus ussuriensis Nutrition 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 43
- 229940093181 glucose injection Drugs 0.000 abstract description 22
- 238000001914 filtration Methods 0.000 abstract description 18
- 238000002156 mixing Methods 0.000 abstract description 18
- 229940090044 injection Drugs 0.000 abstract description 16
- 238000000034 method Methods 0.000 abstract description 3
- 239000003833 bile salt Substances 0.000 abstract 1
- 238000011049 filling Methods 0.000 abstract 1
- -1 silibinin phospholipid compound Chemical class 0.000 abstract 1
- 239000007788 liquid Substances 0.000 description 68
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 18
- 239000012982 microporous membrane Substances 0.000 description 17
- 239000000706 filtrate Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- FDQAOULAVFHKBX-KMRPREKFSA-N (+)-Isosilybin A Natural products C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC(=CC=C3O2)[C@@H]2[C@@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-KMRPREKFSA-N 0.000 description 2
- FDQAOULAVFHKBX-HKTJVKLFSA-N (2r,3r)-3,5,7-trihydroxy-2-[(2r,3r)-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC(=CC=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-HKTJVKLFSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- KDMGQPNVTKUNHV-UHFFFAOYSA-N Isosilybin Natural products C1=C(O)C(OC)=CC=C1C1C(CO)OC2=CC=C(C3C(C(=O)C4=C(O)C=C(O)C=C4O3)O)C=C2O1 KDMGQPNVTKUNHV-UHFFFAOYSA-N 0.000 description 2
- FDQAOULAVFHKBX-UHFFFAOYSA-N Isosilybin A Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC(=CC=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-UHFFFAOYSA-N 0.000 description 2
- CYGIJEJDYJOUAN-UHFFFAOYSA-N Isosilychristin Natural products C1=C(O)C(OC)=CC(C2C3C=C(C4C(C3=O)(O)OCC42)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 CYGIJEJDYJOUAN-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 244000272459 Silybum marianum Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- RIAZZJBPJQWPIS-UHFFFAOYSA-N Silychristin Natural products COc1cc(ccc1O)C2OC3C(C=C(C=C3O)C4Oc5cc(O)cc(O)c5C(=O)C4O)C2CO RIAZZJBPJQWPIS-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000011208 chromatographic data Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 229950004304 silidianin Drugs 0.000 description 1
- BMLIIPOXVWESJG-LMBCONBSSA-N silychristin Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@@H](C3=C(C(=CC(=C3)[C@@H]3[C@H](C(=O)C4=C(O)C=C(O)C=C4O3)O)O)O2)CO)=C1 BMLIIPOXVWESJG-LMBCONBSSA-N 0.000 description 1
- BMLIIPOXVWESJG-UHFFFAOYSA-N silychristin A Natural products C1=C(O)C(OC)=CC(C2C(C3=C(C(=CC(=C3)C3C(C(=O)C4=C(O)C=C(O)C=C4O3)O)O)O2)CO)=C1 BMLIIPOXVWESJG-UHFFFAOYSA-N 0.000 description 1
- CYGIJEJDYJOUAN-JSGXPVSSSA-N silydianin Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@H]3C=C([C@@H]4[C@@](C3=O)(O)OC[C@@H]42)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 CYGIJEJDYJOUAN-JSGXPVSSSA-N 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (26)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910069801.2A CN101953794B (zh) | 2009-07-21 | 2009-07-21 | 一种水飞蓟宾注射剂及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910069801.2A CN101953794B (zh) | 2009-07-21 | 2009-07-21 | 一种水飞蓟宾注射剂及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101953794A true CN101953794A (zh) | 2011-01-26 |
CN101953794B CN101953794B (zh) | 2014-05-14 |
Family
ID=43481555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200910069801.2A Expired - Fee Related CN101953794B (zh) | 2009-07-21 | 2009-07-21 | 一种水飞蓟宾注射剂及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101953794B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105476966A (zh) * | 2016-01-29 | 2016-04-13 | 中国药科大学 | 一种水飞蓟宾磷脂复合物纳米冻干粉及其制备方法 |
CN105983018A (zh) * | 2015-03-23 | 2016-10-05 | 天士力制药集团股份有限公司 | 一种含有水飞蓟宾的药物组合物 |
WO2017081140A1 (en) * | 2015-11-12 | 2017-05-18 | Istituto Biochimico Italiano Giovanni Lorenzini S.P.A. | An oral drug formulation comprising silybin |
CN114403267A (zh) * | 2022-01-24 | 2022-04-29 | 浙江欣诺医药有限公司 | 一种莓茶活性粉及其固体饮料 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1709238A (zh) * | 2005-07-06 | 2005-12-21 | 鲁南制药集团股份有限公司 | 一种具有保肝作用的静脉注射用粉针及其制备与质量控制方法 |
CN1732918A (zh) * | 2005-08-25 | 2006-02-15 | 江苏大学 | 水飞蓟宾纳米制剂药物及其制备方法 |
CN101062030A (zh) * | 2006-04-26 | 2007-10-31 | 哈药集团中药二厂 | 一种水飞蓟宾冻干粉针的制备方法 |
CN101108179A (zh) * | 2006-07-17 | 2008-01-23 | 广州瑞济生物技术有限公司 | 一种水飞蓟素的药物制剂及其制备方法 |
CN101157689A (zh) * | 2007-11-14 | 2008-04-09 | 南京克温生物科技有限公司 | 一种水飞蓟宾和苦参素或苦参碱的复盐及其应用 |
CN101548967A (zh) * | 2008-04-03 | 2009-10-07 | 北京本草天源药物研究院 | 一种药物组合物 |
-
2009
- 2009-07-21 CN CN200910069801.2A patent/CN101953794B/zh not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1709238A (zh) * | 2005-07-06 | 2005-12-21 | 鲁南制药集团股份有限公司 | 一种具有保肝作用的静脉注射用粉针及其制备与质量控制方法 |
CN1732918A (zh) * | 2005-08-25 | 2006-02-15 | 江苏大学 | 水飞蓟宾纳米制剂药物及其制备方法 |
CN101062030A (zh) * | 2006-04-26 | 2007-10-31 | 哈药集团中药二厂 | 一种水飞蓟宾冻干粉针的制备方法 |
CN101108179A (zh) * | 2006-07-17 | 2008-01-23 | 广州瑞济生物技术有限公司 | 一种水飞蓟素的药物制剂及其制备方法 |
CN101157689A (zh) * | 2007-11-14 | 2008-04-09 | 南京克温生物科技有限公司 | 一种水飞蓟宾和苦参素或苦参碱的复盐及其应用 |
CN101548967A (zh) * | 2008-04-03 | 2009-10-07 | 北京本草天源药物研究院 | 一种药物组合物 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105983018A (zh) * | 2015-03-23 | 2016-10-05 | 天士力制药集团股份有限公司 | 一种含有水飞蓟宾的药物组合物 |
CN105983015A (zh) * | 2015-03-23 | 2016-10-05 | 天士力制药集团股份有限公司 | 一种含有水飞蓟宾、ve的药物组合物 |
CN105983015B (zh) * | 2015-03-23 | 2022-01-25 | 天士力医药集团股份有限公司 | 一种含有水飞蓟宾、ve的药物组合物 |
CN105983018B (zh) * | 2015-03-23 | 2022-06-03 | 天士力医药集团股份有限公司 | 一种含有水飞蓟宾的药物组合物 |
WO2017081140A1 (en) * | 2015-11-12 | 2017-05-18 | Istituto Biochimico Italiano Giovanni Lorenzini S.P.A. | An oral drug formulation comprising silybin |
CN105476966A (zh) * | 2016-01-29 | 2016-04-13 | 中国药科大学 | 一种水飞蓟宾磷脂复合物纳米冻干粉及其制备方法 |
CN114403267A (zh) * | 2022-01-24 | 2022-04-29 | 浙江欣诺医药有限公司 | 一种莓茶活性粉及其固体饮料 |
Also Published As
Publication number | Publication date |
---|---|
CN101953794B (zh) | 2014-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103096907B (zh) | 可用于减轻炎症和外周疼痛的含有狭叶紫锥菊和姜的提取物的制剂 | |
CN101953794B (zh) | 一种水飞蓟宾注射剂及制备方法 | |
Zhou et al. | Effect of sodium caprate on the oral absorptions of danshensu and salvianolic acid B | |
JP2022530752A (ja) | フラボノイドポリフェノール系薬剤の自己乳化組成物、その調製方法、医薬組成物および使用 | |
CN105748408A (zh) | 微乳、微乳制剂及其制备方法 | |
Yan et al. | Pharmacokinetic study of ferulic acid following transdermal or intragastric administration in rats | |
JP2015523361A5 (ja) | 低分子薬の非経口注射用の安定な製剤 | |
CN104208288A (zh) | 一种抗炎镇痛外用制剂及其制备方法与用途 | |
CN101185638B (zh) | 一种微乳制剂及其制备方法 | |
Zhang et al. | A Novel Berberine–Glycyrrhizic Acid Complex Formulation Enhanced the Prevention Effect to Doxorubicin-Induced Cardiotoxicity by Pharmacokinetic Modulation of Berberine in Rats | |
CN101669986A (zh) | 一种含有苦豆子油的复方凝胶制剂 | |
CN100525758C (zh) | 藤黄酸脂质体及其冻干粉针剂与制备方法 | |
CN104510853A (zh) | 一种治疗妇女痛经的中药有效部位组合物及其用途 | |
CN101797278A (zh) | 雷公藤总萜囊泡及其制备方法 | |
CN103330941B (zh) | 一种紫杉醇注射剂的药物组合物 | |
CN104146959A (zh) | 冬凌草甲素缓释脂质体及其制备方法 | |
CN109758582A (zh) | 一种穿透血脑屏障的聚山梨酯80及其组分形成的载药胶束递送系统 | |
CN102755297A (zh) | 一种七叶皂苷b冻干粉针剂及其制备方法和应用 | |
CN100382799C (zh) | 一种具有保肝作用的静脉注射用粉针及其制备与质量控制方法 | |
CN103623345B (zh) | 抗病毒口服液的制备方法 | |
CN103893125B (zh) | 阿尼芬净纳米粒及其制备方法 | |
CN101837004A (zh) | 薯蓣皂苷在制备肝保护药物制剂中的应用 | |
CN101766703B (zh) | 含有冰片、麝香的药物组合物 | |
CN101766702B (zh) | 含有冰片、麝香的药物组合物 | |
CN116019780B (zh) | 一种双黄纳米颗粒及其制备与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Applicant after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Applicant before: TIANJIN TASLY PHARMACEUTICAL Co.,Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: TIANJIN TASLY PHARMACEUTICAL CO., LTD. TO: TASLY PHARMACEUTICAL GROUP CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee before: TASLY PHARMACEUTICAL GROUP Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140514 Termination date: 20210721 |